UCLA researchers in the Department of Chemical and Biomolecular Engineering have developed a novel biomaterial that can be used as a therapeutic for cancer, wound healing and other diseases.
Immunotherapy, the modulation of immune response to drive tissue-specific expression has tremendous potential as a therapeutic for malignant cancers and for wound healing. It can also be used for vaccination. However, such an approach requires an immune modulator that can cause a local, sustained immune response without side effects and is not prone to clearance.
UCLA researchers have developed a novel biomaterial with immune-modulatory properties. Their approach is based on a solid hydrogel with chemically cross-linked immune modulators. It is not prone to clearance and is stable for long time periods ensuring a sustained immune response. Their initial proof of concept experiments showed an eight-fold increase in expression of immune cells around the biomaterial.
Proof of concept experiments conducted in animal model systems.
|United States Of America||Published Application||2019-014296||05/16/2019||2016-788|
|European Patent Office||Published Application||3439697||02/13/2019||2016-788|
Hydrogel, Immune response, Immune system, Immune modulation, Inflammation, Inflammatory response, Cancer, Wound healing